Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if self-administered oral resveratrol can dampen joint pain for individuals with pseudoachondroplasia compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Treatments: Resveratrol

Criteria

Inclusion Criteria:

• The diagnosis of pseudoachondroplasia is based on clinical assessment either in person or by photographic review by skeletal dysplasia specialist (JTH),

• Healthy beyond pseudoachondroplasia associated complications,

Exclusion Criteria:

• Current use of resveratrol

• Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine and triazolam.

• Other non-pseudoachondroplasia related health conditions, e.g. cancers.

• Pregnancy or breastfeeding. Women must use adequate contraception during the study.

• Participation in another clinical study and/or using investigational agents.

• Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.

• Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine, Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir, Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine, Fosphenytoin, Phenytoin or Warfarin.

• Baseline level of pain of 2 or higher on 10 point scale.

• Platelet count below 50,000 per ul on baseline complete blood count (CBC).